Ditlev E. Brodersen appointed Hallas-Møller Ascending Investigator



News

Ditlev E. Brodersen receives DKK 10 mio. from the Novo Nordisk Foundation to study how microorganisms defend themselves. The research will be of great importance for the treatment of infectious diseases in the future. Photo: Lars Kruse, AU-foto.

2018.04.04 | Grant

Ditlev E. Brodersen is among the first to be appointed Novo Nordisk Foundation Hallas-Møller Ascending Investigator

As one of the first researchers in the country, Associate Professor Ditlev E. Brodersen receives the Hallas-Møller Ascending Investigator grant as part of the Novo Nordisk Foundation Research Leader Programme. The 10 mio DKK (ca. Euro 1,342,320) grant will provide Ditlev Brodersen's research lab with opportunities to explore the survival…

Postdoc Peter Refsing Andersen has been awarded a Hallas-Møller Emerging Investigator grant of DKK 10 mio. over the next five years to establish a research group at the Department of Molecular Biology and Genetics, AU, to study genetic parasites. Photo: Ernst Tobisch.

2018.04.04 | Grant

Peter Refsing Andersen awarded the Hallas-Møller Emerging Investigator grant

Postdoc Peter Refsing Andersen from the Institute of Molecular Biotechnology (IMBA) at Vienna BioCenter in Austria has been awarded a Hallas-Møller Emerging Investigator grant of DKK 10 mio. (ca. Euro 1,342,320) over the next five years to establish a research group at the Department of Molecular Biology and Genetics, AU, to study genetic…

From the opening ceremony: (from left) Jens Peter Holst Lauritsen from the Novo Nordisk Foundation, Jørgen Kjems from MBG and iNANO, Kurt V. Gothelf from Chemistry and iNANO and Ken Howard from MBG and iNANO, and iNANO Center Manager, Trolle Linderoth. Photo: Roar Paaske.

2018.03.21 | Grant

Starting signal for the multifunctional medicine of the future

The potential for the research now being addressed by the Center for Multifunctional Biomolecular Drug Design (CEMBID) at Aarhus University is enormous. The goal is to create a new generation of drugs that can be used to diagnose and treat cancer and atherosclerosis - which together represent two thirds among the causes of death globally.

Left panel of the figure displays the structure of the newly developed nanobody (magenta) bound to a C3 fragment called C3b (green). In the right panels, data demonstrating that the nanobody and mutants hereof are able to inhibit the cleavage of C3 in 15% human serum. The researchers also constructed a nanobody mutant that completely loses it inhibitory effect on C3 cleavage (purple curve) making it a perfect negative control. Figure: Rasmus Kjeldsen Jensen and Janus Asbjørn Schatz-Jakobsen.

2018.03.15 | Research

A small protein with many applications

Researchers from the Department of Molecular Biology and Genetics and from the Department of Biomedicine at Aarhus University have collaboratively developed and described a llama-antibody that might have significant impact for future diagnostics and treatment of, e.g., kidney diseases.

Events

Tue 24 Apr
13:00-14:00 | Building 5125, room 114, Finlandsgade 22, 8200 Aarhus N
Guest lecture: Jaehong Han: Production of rare flavonoids by human intestinal bacteria
Thu 26 Apr
14:00-18:00 | ”Stakladen” at Aarhus University, Fredrik Nielsens Vej 2, 8000 Aarhus C
Festival of Research
Mon 30 Apr
09:00-10:00 | Meeting room 1, AU conference centre, Fredrik Nielsens Vej 4, Building 1421
MBG Focus Talk: Lois Banta: Modulation of host defenses by the Type VI Secretion System (T6SS) of Agrobacterium tumefaciens

PhD defences

Ewa Molska

2018.04.10 | PhD defense

Ewa Molska: Diverse RNA classes use common maturation pathways

PhD defense, Tuesday 10 April 2018 Ewa Molska

Nadia Sukusu Nielsen

2018.04.04 | Talent development

Nadia Sukusu Nielsen: Investigation of the Disease Mechanisms of TGFBI-linked Corneal Dystrophies

PhD defence, Wednesday 4 April 2018, Nadia Sukusu Nielsen.